Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 9:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1873–1896 of 14,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Diffuse, Tenosynovial Giant Cell Tumor, Localized
Interventions: Vimseltinib, Placebo; Drug
Lead sponsor: Deciphera Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 11
States / cities: Duarte, California • Sacramento, California • Aurora, Colorado + 8 more

Conditions: Venous Stasis Ulcers
Interventions: Revera Wound Care, Normal Saline; Device
Lead sponsor: Revalesio Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Diabetic Neuropathic Pain
Interventions: ABT-894, placebo; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 75 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 12
States / cities: Spring Valley, California • Walnut Creek, California • Hollywood, Florida + 8 more

Conditions: Influenza
Interventions: Cell-Derived Trivalent Subunit Influenza Vaccine, Placebo; Biological
Lead sponsor: Abbott Biologicals; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 1,270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 15
States / cities: Jacksonville, Florida • Pembroke Pines, Florida • South Miami, Florida + 12 more

Conditions: Hemophilia A
Interventions: BAY94-9027; Biological
Lead sponsor: Bayer; Industry
Eligibility: Up to 12 Years · Male only
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 7
States / cities: Sacramento, California • Pensacola, Florida • Cincinnati, Ohio + 4 more

Conditions: Covid19, Post-acute COVID-19 Respiratory Disease
Interventions: LYT-100, Placebo; Drug · Other
Lead sponsor: PureTech; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 15
States / cities: Birmingham, Alabama • Florence, Alabama • Los Angeles, California + 12 more

Conditions: Alzheimer Disease
Interventions: bapineuzumab, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 901 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 164
States / cities: Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 98 more

Conditions: Endometrial Hyperplasia, Osteoporosis
Interventions: Bazedoxifene/Conjugated Estrogen, CE 0.45 mg/MPA 1.5mg, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 1,083 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 9
States / cities: Upland, California • Inverness, Florida • West Palm Beach, Florida + 6 more

Conditions: Cholera, Cholera Vaccine Toxicity
Interventions: PanChol; Biological
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 55 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Early Stage Parkinson's Disease
Interventions: Aplindore, Placebo; Drug
Lead sponsor: Ligand Pharmaceuticals; Industry
Eligibility: 30 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Coagulopathy
Interventions: Resusix, FP24 (Frozen Plasma); Biological
Lead sponsor: Entegrion, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 3
States / cities: Tucson, Arizona • St Louis, Missouri • Charlotte, North Carolina

Conditions: Atherosclerosis
Interventions: Darapladib 160 mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Orlando, Florida • Minneapolis, Minnesota

Conditions: Adjunctive Treatment of Major Depressive Disorder
Interventions: Pimavanserin, Placebo; Drug
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 41
States / cities: Birmingham, Alabama • Garden Grove, California • Glendale, California + 34 more

Conditions: Generalized Anxiety Disorder
Interventions: PD 0332334, paroxetine, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 27
States / cities: Birmingham, Alabama • Glendale, California • Orange, California + 22 more

Conditions: Cystic Fibrosis
Interventions: Nitric Oxide 160 ppm; Drug
Lead sponsor: Novoteris, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 6
States / cities: Garden Grove, California • Los Angeles, California • Columbus, Ohio + 3 more

Conditions: Menopausal and Female Climacteric States
Interventions: Other: Placebo, GSK232802, PREMARIN; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 41
States / cities: Chandler, Arizona • Glendale, Arizona • Scottsdale, Arizona + 35 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: MEDI8897 Intravenous, Placebo, MEDI8897 Intramuscular; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 342 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: APOL1-mediated Kidney Disease
Interventions: VX-840, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Erectile Dysfunction
Interventions: Sildenafil Cream, Placebo Cream, Penile Plethysmography (RigiScan); Drug · Device
Lead sponsor: Strategic Science & Technologies, LLC; Industry
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 3
States / cities: San Diego, California • New Orleans, Louisiana • New York, New York

Conditions: Anterior Cruciate Ligament Reconstruction
Interventions: AirBand, uninflated AirBand; Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Milford, Connecticut • North Haven, Connecticut

Conditions: Non-alcoholic Steatohepatitis
Interventions: NNC0194 0499 50 mg/mL, Placebo (NNC0194-0499), Semaglutide 3 mg/mL, Semaglutide placebo, NNC0174 0833 10 mg/mL, NNC0174 0833 placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Not listed
Enrollment: 698 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 70
States / cities: Huntsville, Alabama • Chandler, Arizona • Peoria, Arizona + 59 more

Conditions: Eosinophilic Asthma
Interventions: Reslizumab, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 15
States / cities: Mobile, Alabama • Fresno, California • Long Beach, California + 12 more

Conditions: Gastroesophageal Reflux Disease (GERD)
Interventions: Open Label Run In Esomeprazole, Double Blind Esomeprazole, Double Blind Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 1 Month to 11 Months
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 14
States / cities: Phoenix, Arizona • Atlanta, Georgia • Park Ridge, Illinois + 11 more

Conditions: Diabetes Mellitus, Type 2
Interventions: placebo, linagliptin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 60 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 38
States / cities: Sheffield, Alabama • Chula Vista, California • Costa Mesa, California + 32 more

Search by objective public record fields.

Study of Vimseltinib for Tenosynovial Giant Cell Tumor

Feasibility Study to Evaluate the Safety of Topically Applied Revera in Subjects With Venous Leg Ulcers

A Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain

Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Adults Aged >= 18 and <= 64, Plus Revaccination

Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A

LYT-100 in Post-acute COVID-19 Respiratory Disease

Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients

Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women

First in Human Phase 1 Ascending Dose Study of PanChol in Healthy Volunteers

The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's Disease

Comparison of the Efficacy & Safety of Resusix With FP24 in Patients With Acquired Coagulopathy

A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Doses of Darapladib (SB-480848) in Subjects With Severe Renal Impairment

Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)

Efficacy and Safety of Inhaled Nitric Oxide (NO) in Cystic Fibrosis (CF) Patients

Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults

A Phase 1 Dose Escalation Study to Evaluate Safety and Pharmacokinetics (PK) of VX-840 in Healthy Participants

Phase 2a Topical Sildenafil Proof-of-Concept Study in Men With Mild to Moderate ED

Immunometabolic Mechanisms of Blood Flow Restriction (BFR) Training After Anterior Cruciate Ligament Reconstruction

Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma

Phase 3/Safety & Efficacy of Esomeprazole in Infants

Linagliptin as Add on to Basal Insulin in the Elderly